IPO rating | Ruike Bio-B: impact on "Hong Kong Stock HPV Vaccine No.1"

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

IPO rating | Ruike Bio-B: impact on "Hong Kong Stock HPV Vaccine No.1"

uSMART盈立智投 03-21 09:52

Today I bring you the new stock rating of [Ruike Bio-B]. This rating is mainly based on the two dimensions of the basic market and the actual market, and the core indicators of the target company are scored with a full score of 10 points, and each index is scored separately, calculated according to the sum of (weight ratio * score). The final result is rounded. According to the published data and the exclusive internal rating system, the comprehensive evaluation score of the new shares given to [Ruike Bio-B] is [8.2] (out of 10), as shown in the following figure: